poisar

Stocks · News reference

Alvotech And LOTTE Biologics Announce Long-Term Strategic Manufacturing Partnership For Biosimilar Products

Benzinga Newsdesk

Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New YorkStrategic long-term partnership to increase Alvotech’s global manufacturing capacity and support

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ALVO
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Na

    Alvotech kemur fram á fjórum fjárfestaráðstefnum í nóvember

    Alvotech, a global biotechnology company specializing in biosimilar medicines, will present at four international investor conferences in November 2026 across the UK, Norway, and Sweden. The company will participate in UBS's biotech conference in London, Jefferies' healthcare conference in London, DNB Carnegie's healthcare conference in Oslo, and SEB's healthcare conference in Stockholm. Live streams and recordings of these presentations will be available on the company's events page.

    ALVOALVOW
  3. Not Specified

    Alvotech to Present at Upcoming Investor Conferences in November

    Alvotech, a global biotechnology company specializing in biosimilar medicines, announced that its management team will participate in four major investor conferences across Europe in November 2026, including presentations at UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, DNB Carnegie Healthcare Conference, and SEB Healthcare Seminar. Live audio webcasts will be available on the company's website.

    ALVOALVOW
  5. Na

    Alvotech birtir uppgjör fyrstu níu mánaða ársins 2026 þann 11. nóvember nk.

    Alvotech announced it will release its nine-month financial results for 2026 on November 11, with a live webcast presentation scheduled for November 12. The company also received FDA approval for an enhanced SIMLANDI® manufacturing process that more than doubles output per batch, increasing manufacturing productivity and freeing capacity to support growing demand across its biosimilars portfolio.

    ALVOALVOW